Lunaphore deploys COMET™ at Propath UK
Lunaphore, a Swiss life sciences company developing technologies to enable spatial biology in every laboratory, today announced that it has deployed its COMET™ PA instrument at Propath UK, one of Europe’s leading contract research organizations (CRO). Propath UK, a specialist in spatial proteomics and transcriptomics, is the first CRO in Europe to offer COMET™ services to researchers and the first organization to join Lunaphore’s Partner Labs Network, a network of CROs and academic core facilities that offer Lunaphore spatial biology solutions as a service to biopharmaceutical and academic researchers.
COMET™ is a strategic investment for Propath UK to expand its spatial biology service offerings with hyperplex staining and imaging, providing its biopharmaceutical research clients with unprecedented insights from tissue samples to answer biological questions. Lunaphore and Propath UK will work closely to provide a flexible service that meets the needs of researchers across various disciplines.
“We are delighted to form this partnership with Lunaphore and be able to offer our biopharmaceutical clients this highly innovative technology for spatial analysis,” said Dr. Krish Soni, Chief Executive of Propath UK. “We look forward to working closely with Lunaphore to help our clients unlock the incredible potential of hyperplex immunofluorescence through our world-class facility dedicated to spatial biology.”
“My team’s previous experience using COMET™ in a variety of applications at the University of Birmingham allowed us to validate the COMET™’s ability to produce staining results of exceptional quality and reproducibility and provided us the confidence to select Lunaphore as Propath’s hyperplex solution partner,” added Kelly Hunter, Chief Scientific Officer at Propath UK.
COMET™ is a fully automated sequential immunofluorescence (seqIF™) instrument, able to perform hyperplex staining and imaging, producing high-quality data in a robust and reproducible manner. With superior tissue profiling capabilities, the system allows multiplex analysis of up to 40 different spatial markers per tissue slide without human intervention. COMET™ has a wide range of research applications, allowing for a dramatic improvement in the understanding of disease pathology in areas such as immuno-oncology, neuroscience, and infectious diseases.
“We are excited to partner with Propath UK to expand their spatial biology capabilities,” said Ata Tuna Ciftlik, Chief Executive Officer at Lunaphore. “Propath UK is a highly specialized CRO with spatial biology capabilities who can bring spatial biology solutions to BioPharma. We quickly realized that combining the know-how of the Propath UK team and the versatility of COMET™, with its flexible and streamlined panel development capability using validated antibodies, we will be able to bring outstanding results to the end customers.”
To learn more about the COMET™ PA platform, please visit: https://lunaphore.com/products/comet/
To learn more about Lunaphore, please visit: https://lunaphore.com/
To learn more about Propath UK, please visit: https://propath.co.uk
Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore has developed a game-changing chip technology which can extract spatial proteomic and genomic data from tumors and transform any simple assay into multiplex spatial biology without complexity. Lunaphore empowers researchers to push the boundaries of research to ultimately develop the next generation personalized therapies. For further information on Lunaphore and its products, please visit www.lunaphore.com.
About Propath UK
Propath UK is a specialist CRO providing research services in molecular pathology, spatial biology and histopathology for the global biopharmaceutical sector. The company offers a range of technologies for spatial proteomic and transcriptomic tissue analysis, including now the Lunaphore COMET™ platform for hyperplex IHC analysis. Propath’s reputation has been gained over the past 40 years by providing a consistent and responsive service across thousands of pre-clinical and clinical studies. To learn more, please visit www.propath.co.uk.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220503005687/en/
Lunaphore Corporate Communications
Propath UK media enquiries
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AriBio Co., Ltd. to Present Biomarker Data for AR1001 from the Mild to Moderate Alzheimer’s Disease Phase 2 Study at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2023)31.3.2023 18:00:00 CEST | Press release
AriBio Co., Ltd. announced that David Greeley MD, Chief Medical Officer at AriBio, will present biomarker data from the completed phase 2 study in patients with mild to moderate Alzheimer’s disease who were treated with 10mg and 30mg of AR1001. AR1001 is a potent PDE5 inhibitor with preliminary efficacy in cognition, and preclinical effects on neuron apoptosis inhibition, promotion of neurogenesis, increase in neuroplasticity, and stimulation of autophagy to remove toxic proteins. The phase 2 study was a double-blind, randomized, placebo-controlled, multi-center trial to evaluate the safety and preliminary efficacy of AR1001 over 26 and 52 weeks of treatment in patients with mild to moderate Alzheimer’s disease. The trial enrolled 210 patients at 21 research centers in the United States. Plasma collected from patients at baseline, week 26 and week 52 was analyzed by Quantarix using the Simoa HD-X analyzer. Meaningful, statistically significant changes were found over 52 weeks of treatm
KANEKA: “Development of Polymer Synthesis Technology by Microorganisms using CO2 as Direct Raw Material” selected as a NEDO Green Innovation Fund Project”31.3.2023 16:09:00 CEST | Press release
Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka; hereinafter "Kaneka"), Bacchus Bio innovation Co., Ltd (Headquarters: Kobe-city, Hyogo; President: Mikio Tanji; hereinafter "Bacchus"), JGC Holdings Corporation (Headquarters: Yokohama-city Kanagawa; Chairman and CEO: Masayuki Sato; hereinafter "JGC HD"), and Shimadzu Corporation (Headquarters: Kyoto-city, Kyoto; President: Yasunori Yamamoto; hereinafter "Shimadzu") have announced that the proposal of a joint project, “Development of Polymer Synthesis Technology by microorganisms using CO2 as direct raw material (hereinafter referred to as ‘the Project’)” had been selected by the "Green Innovation Fund Project*1 / Promotion of Carbon Recycling Using CO2 from Biomanufacturing Technology as a Direct Raw Material” as a planned implementation sponsored by the New Energy and Industrial Technology Development Organization (NEDO). This press release features multimedia. View the full release here: https://www.busine
Allianz Appoints Leadership for Allianz Commercial Key Markets31.3.2023 15:11:00 CEST | Press release
As part of the implementation of its ‘Integrated Commercial’ strategy to better serve the full Commercial segment, Allianz Group today announced the leadership for four of its largest Property and Casualty Commercial insurance markets: Australia, France, Germany and the United Kingdom. In each country, the appointed single Commercial lead will represent the integrated Allianz Commercial business and bring to the market Allianz’s full set of solutions for specialty clients, large corporates, and mid-sized companies, simplifying and enhancing the experience of clients and distribution partners. “The appointment of the regional leaders in our core Allianz Commercial markets is an important, concrete step toward realizing our new integrated model, which brings together our Mid Corporate and Large Corporate insurance business for the benefit of our clients and distribution partners,” said Chris Townsend, Member of the Allianz SE Board of Management. Townsend added, “As one face to the marke
Huawei Releases 2022 Annual Report: Steady Operations, Sustainable Survival and Development31.3.2023 11:59:00 CEST | Press release
Huawei released its 2022 Annual Report today. The company reports steady operations throughout 2022, having generated CNY642.3 billion in revenue and CNY35.6 billion in net profits. Huawei continues to strengthen investment in R&D, with an annual expenditure of CNY161.5 billion in 2022, representing 25.1% of the company's annual revenue and bringing its total R&D expenditure over the past 10 years to more than CNY977.3 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230331005166/en/ (Photo: Huawei) "In 2022, a challenging external environment and non-market factors continued to take a toll on Huawei's operations", said Eric Xu, Huawei's Rotating Chairman, at the company's annual report press conference. "In the midst of this storm, we kept racing ahead, doing everything in our power to maintain business continuity and serve our customers. We also went to great lengths to grow the harvest – generating a steady stream
Horizon Quantum Computing Raises USD 18.1 million Series A to Advance Quantum Software Development31.3.2023 09:30:00 CEST | Press release
Horizon Quantum Computing,a Singapore-based company building software development tools to unlock the potential of quantum computing hardware, announced today that it has raised USD 18.1 million Series A investment from Sequoia Capital India, Tencent, SGInnovate, Pappas Capital and Expeditions Fund. The investment round will boost the growth of the company, allowing it to strengthen its science and engineering teams to accelerate product development, establish its new engineering centre in Europe and bring Horizon’s unique technology to the market. Horizon Quantum Computing’s total funding now stands at approximately USD 21.3 million. “Quantum computing has the potential to completely change how we think about computing,” says Horizon’s CEO Dr Joe Fitzsimons. “While getting to large scale quantum computing is a daunting challenge, it is undeniable that progress towards that goal is being made. At Horizon, we focus on unlocking the power of future quantum computers, and have made signif
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom